Kymera Therapeutics (KYMR) Competitors $41.20 -0.55 (-1.32%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$41.78 +0.58 (+1.41%) As of 08/29/2025 05:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock KYMR vs. VTRS, RDY, ASND, QGEN, MRNA, BBIO, ELAN, VRNA, ROIV, and GRFSShould you be buying Kymera Therapeutics stock or one of its competitors? The main competitors of Kymera Therapeutics include Viatris (VTRS), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Qiagen (QGEN), Moderna (MRNA), BridgeBio Pharma (BBIO), Elanco Animal Health (ELAN), Verona Pharma PLC American Depositary Share (VRNA), Roivant Sciences (ROIV), and Grifols (GRFS). These companies are all part of the "pharmaceutical products" industry. Kymera Therapeutics vs. Its Competitors Viatris Dr. Reddy's Laboratories Ascendis Pharma A/S Qiagen Moderna BridgeBio Pharma Elanco Animal Health Verona Pharma PLC American Depositary Share Roivant Sciences Grifols Viatris (NASDAQ:VTRS) and Kymera Therapeutics (NASDAQ:KYMR) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, dividends, media sentiment, valuation, profitability, institutional ownership, risk and analyst recommendations. Do analysts prefer VTRS or KYMR? Viatris presently has a consensus price target of $10.40, suggesting a potential downside of 1.42%. Kymera Therapeutics has a consensus price target of $58.76, suggesting a potential upside of 42.63%. Given Kymera Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Kymera Therapeutics is more favorable than Viatris.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Viatris 2 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.80Kymera Therapeutics 0 Sell rating(s) 1 Hold rating(s) 15 Buy rating(s) 3 Strong Buy rating(s) 3.11 Do institutionals and insiders hold more shares of VTRS or KYMR? 79.9% of Viatris shares are owned by institutional investors. 0.1% of Viatris shares are owned by company insiders. Comparatively, 16.0% of Kymera Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Does the media refer more to VTRS or KYMR? In the previous week, Kymera Therapeutics had 2 more articles in the media than Viatris. MarketBeat recorded 7 mentions for Kymera Therapeutics and 5 mentions for Viatris. Kymera Therapeutics' average media sentiment score of 1.57 beat Viatris' score of 0.12 indicating that Kymera Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viatris 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Kymera Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Is VTRS or KYMR more profitable? Viatris has a net margin of -24.57% compared to Kymera Therapeutics' net margin of -616.03%. Viatris' return on equity of 16.54% beat Kymera Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Viatris-24.57% 16.54% 7.06% Kymera Therapeutics -616.03%-31.60%-27.12% Which has more volatility and risk, VTRS or KYMR? Viatris has a beta of 0.93, indicating that its stock price is 7% less volatile than the S&P 500. Comparatively, Kymera Therapeutics has a beta of 2.17, indicating that its stock price is 117% more volatile than the S&P 500. Which has better valuation & earnings, VTRS or KYMR? Kymera Therapeutics has lower revenue, but higher earnings than Viatris. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Viatris, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioViatris$14.74B0.83-$634.20M-$2.90-3.64Kymera Therapeutics$47.07M62.58-$223.86M-$3.47-11.87 SummaryKymera Therapeutics beats Viatris on 10 of the 16 factors compared between the two stocks. Get Kymera Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KYMR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KYMR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KYMR vs. The Competition Export to ExcelMetricKymera TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.95B$3.07B$5.75B$9.76BDividend YieldN/A2.29%4.08%4.04%P/E RatioN/A20.7883.2726.60Price / Sales62.58386.53541.17113.73Price / CashN/A44.2237.4459.26Price / Book3.198.0710.556.58Net Income-$223.86M-$53.98M$3.27B$265.95M7 Day Performance-6.58%-0.88%0.40%0.17%1 Month Performance-5.83%7.72%7.31%3.90%1 Year Performance-14.81%7.03%46.58%19.67% Kymera Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KYMRKymera Therapeutics3.0252 of 5 stars$41.20-1.3%$58.76+42.6%-14.8%$2.95B$47.07M0.00170News CoveragePositive NewsVTRSViatris1.8347 of 5 stars$10.55-0.9%$10.40-1.4%-12.7%$12.42B$14.12B-3.6432,000RDYDr. Reddy's Laboratories2.8757 of 5 stars$14.46-0.4%$16.95+17.3%-15.0%$12.11B$3.81B21.9027,811News CoveragePositive NewsASNDAscendis Pharma A/S3.3482 of 5 stars$190.37-2.0%$243.36+27.8%+40.3%$11.89B$393.54M-36.891,017News CoveragePositive NewsQGENQiagen3.799 of 5 stars$48.92-1.6%$49.69+1.6%+4.8%$11.06B$1.98B28.905,765Trending NewsAnalyst RevisionMRNAModerna4.514 of 5 stars$25.35-6.5%$42.88+69.2%-68.9%$10.55B$3.06B-3.375,800BBIOBridgeBio Pharma4.2489 of 5 stars$47.29-3.6%$61.35+29.7%+85.9%$9.38B$235.81M-11.56400News CoveragePositive NewsAnalyst ForecastELANElanco Animal Health2.7747 of 5 stars$17.80-0.6%$17.33-2.6%+18.8%$8.90B$4.48B20.709,000VRNAVerona Pharma PLC American Depositary Share2.4247 of 5 stars$105.62+0.1%$109.00+3.2%+285.4%$8.64B$221.67M-106.6930Positive NewsROIVRoivant Sciences3.1796 of 5 stars$11.64-2.3%$16.50+41.8%-2.5%$8.14B$29.05M-16.63860News CoveragePositive NewsGRFSGrifols3.5505 of 5 stars$9.82-3.3%$10.30+4.9%+6.7%$6.99B$7.81B8.3923,822 Related Companies and Tools Related Companies VTRS Competitors RDY Competitors ASND Competitors QGEN Competitors MRNA Competitors BBIO Competitors ELAN Competitors VRNA Competitors ROIV Competitors GRFS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KYMR) was last updated on 8/31/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kymera Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kymera Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
